Mitra-Majumdar M - Search Results

1

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs.

Mitra-Majumdar M, Powers JH 3rd, Brown BL, Kesselheim AS. Mitra-Majumdar M, et al. BMJ Med. 2022 Dec 12;1(1):e000227. doi: 10.1136/bmjmed-2022-000227. eCollection 2022. BMJ Med. 2022. PMID: 36936591 Free PMC article.

2

Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016.

Brown BL, Mitra-Majumdar M, Darrow JJ, Moneer O, Pham C, Avorn J, Kesselheim AS. Brown BL, et al. Among authors: mitra majumdar m. JAMA Intern Med. 2022 Oct 3;182(11):1223-6. doi: 10.1001/jamainternmed.2022.4226. Online ahead of print. JAMA Intern Med. 2022. PMID: 36190713 Free PMC article.

3

Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review.

Brown BL, Mitra-Majumdar M, Joyce K, Ross M, Pham C, Darrow JJ, Avorn J, Kesselheim AS. Brown BL, et al. Among authors: mitra majumdar m. J Health Polit Policy Law. 2022 Dec 1;47(6):649-672. doi: 10.1215/03616878-10041093. J Health Polit Policy Law. 2022. PMID: 35867548

4

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.

Mitra-Majumdar M, Gunter SJ, Kesselheim AS, Brown BL, Joyce KW, Ross M, Pham C, Avorn J, Darrow JJ. Mitra-Majumdar M, et al. JAMA Netw Open. 2022 May 2;5(5):e2212454. doi: 10.1001/jamanetworkopen.2022.12454. JAMA Netw Open. 2022. PMID: 35579897 Free PMC article.

5

New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence.

Moneer O, Brown BL, Avorn J, Darrow JJ, Mitra-Majumdar M, Joyce KW, Ross M, Pham C, Kesselheim AS. Moneer O, et al. Among authors: mitra majumdar m. Drug Saf. 2022 Apr;45(4):305-318. doi: 10.1007/s40264-022-01152-9. Epub 2022 Feb 19. Drug Saf. 2022. PMID: 35182362

6

Reporting bias in clinical trials: Progress toward transparency and next steps.

Mitra-Majumdar M, Kesselheim AS. Mitra-Majumdar M, et al. PLoS Med. 2022 Jan 19;19(1):e1003894. doi: 10.1371/journal.pmed.1003894. eCollection 2022 Jan. PLoS Med. 2022. PMID: 35045078 Free PMC article.

7

A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs.

Sarpatwari A, Mitra-Majumdar M, Bykov K, Avorn J, Woloshin S, Toyserkani GA, LaCivita C, Manzo C, Zhou EH, Pinnow E, Dal Pan GJ, Gagne JJ, Huybrechts KF, Feldman WB, Chin K, Kesselheim AS. Sarpatwari A, et al. Among authors: mitra majumdar m. Drug Saf. 2021 Jul;44(7):743-751. doi: 10.1007/s40264-021-01070-2. Epub 2021 Apr 27. Drug Saf. 2021. PMID: 33904111

8

An Overview Of Vaccine Development, Approval, And Regulation, With Implications For COVID-19.

Kesselheim AS, Darrow JJ, Kulldorff M, Brown BL, Mitra-Majumdar M, Lee CC, Moneer O, Avorn J. Kesselheim AS, et al. Among authors: mitra majumdar m. Health Aff (Millwood). 2021 Jan;40(1):25-32. doi: 10.1377/hlthaff.2020.01620. Epub 2020 Nov 19. Health Aff (Millwood). 2021. PMID: 33211535

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters